THIS COMMUNICATION IS NOT FOR ITS DIFFUSION, PUBLICATION NOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SAID DISTRIBUTION, PUBLICATION OR DIFFUSION IS UNLAWFUL

ORYZON GENOMICS. S.A.

Pursuant to the provisions of article 228 of the Restated Text of the Securities Market Act approved by Royal Legislative Decree 4/2015 of 23 October and article 17 of Regulation (EU) No 596/2014 on market abuse, ORYZON GENOMICS, S.A. ("ORYZON" or the "Company") hereby gives notice of the following

SIGNIFICANT EVENT

Following the significant event communicated on March 31, 2017 under registration number 250161 regarding the share capital increase approved by the Board of Directors of the Company on March 10, 2017 (the "Capital Increase"), the Company informs:

- I. That the Capital Increase deed granted today for a nominal amount of EUR 284,678.25, by means of the issuance and placement into circulation of 5,693,565 new shares (the "New Shares"), has been duly registered with the Commercial Registry of Barcelona.
 - Hence, the new share capital of ORYZON amounts to EUR 1,708,069.55, represented by 34,161,391 shares of EUR 0.05 par value each, all of which belonging to the same class and series.
- II. That on this date, the National Securities Exchange Commission (Comisión Nacional del Mercado de Valores) (the "CNMV") has verified that the requirements for the admission to trading of the New Shares have been met. Likewise, the Securities Note and the Summary, regarding the admission to trading of the New Shares have been duly registered, on this date, in the official registries of the CNMV.
- III. That the New Shares have been admitted to trading on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges through the Automated Quotation System (Continuous Market) on this date, commencing their trading on April 5, 2017.

All of which is communicated for the appropriate purposes in Barcelona, on April 4, 2017.